EQUITY (Details Narrative) - USD ($) | | | | | | | | 1 Months Ended | 3 Months Ended | 12 Months Ended | |
Dec. 23, 2021 | Mar. 29, 2021 | Jun. 23, 2020 | Jun. 22, 2020 | May 18, 2020 | Mar. 15, 2020 | Mar. 03, 2020 | Nov. 30, 2021 | Jun. 30, 2021 | Feb. 28, 2021 | Feb. 29, 2020 | Dec. 31, 2019 | Jun. 30, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Jan. 20, 2021 |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Common stock shares authorized | | | | | | | | | | | | | | 300,000,000 | 300,000,000 | | |
Common stock, par value | | | | | | | | | | | | | | $ 0.001 | $ 0.001 | | |
Proceeds from exercise of warrants | | | | | | | | | | | | | | | $ 3,491,000 | | |
Share based compensation arrangement Options grants in period gross | | | | | | | | | | | | | | 479,000 | 648,712 | | |
Weighted average exercise price | | | | | | | | | | | | | | $ 4.50 | $ 4.09 | | |
Expenses recorded regarding | | | | | | | | | | | | | | $ 576,000 | $ 257,000 | | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award | | | | | | | | | | | | | | 90,000 | | | |
Compensation expense | | | | | | | | | | | | | | $ 1,638,000 | $ 2,030,000 | | |
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value | | | | | | | | | | | | | | $ 127,000 | | | |
Share-Based Payment Arrangement, Option [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Option to purchase | | | | | | | | | | | | | | | 75,855 | | |
Share-Based Payment Arrangement, Option [Member] | Prof Goldwasser [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Option to purchase | | | | | | | | | | | | | | 45,000 | 83,334 | | |
Expenses recorded regarding | | | | | | | | | | | | | | $ 367,000 | $ 255,000 | | |
Equity Option [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Weighted average exercise price | | | | | | | | | | | | | | $ 2.76 | | | |
Stock option award cost not yet recognized | | | | | | | | | | | | | | $ 1,450,000 | | | |
Stock option award weighted average period | | | | | | | | | | | | | | 1 year 4 months 28 days | | | |
Restricted Stock Units (RSUs) [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Share based compensation arrangement Options grants in period gross | | | | | | | | | | | | | | 110,000 | | | |
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value | | | | | | | | | | | | | | $ 748,000 | | | |
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value | | | | | | | | | | | | | | $ 164,000 | | | |
Estimated average period | | | | | | | | | | | | | | 1 year 1 month 24 days | | | |
2020 Share Incentive Plan [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Share based compensation arrangement Options grants in period gross | | | | | | | | | | | | | | 479,000 | 648,712 | | |
Stock option vested term | | | | | | | | | | | | | | 7 years | | | |
2020 Share Incentive Plan [Member] | Minimum [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Stock option vested term | | | | | | | | | | | | | | 3 years | | | |
2020 Share Incentive Plan [Member] | Maximum [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Stock option vested term | | | | | | | | | | | | | | 4 years | | | |
Letter Agreement [Member] | Medigus Ltd [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Conversion price | | | $ 4.356 | | | | | | | | | | | | | | |
Warrant A [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Warrant exercisable, shares | | | 1 | | 1 | | 1 | | | | | | | 1 | | | |
Warrant exerise price per share | | | $ 5.355 | | $ 5.355 | | $ 5.355 | | | | | | | $ 5.355 | | | |
Warrants and rights outstanding, term | | | 12 months | | 18 months | | 12 months | | | | | | | | | | |
Proceeds from exercise of warrants | | | | | | | | | | | | | $ 45,000 | | | $ 53,000 | |
Number of warrants exercised | | | | | | | | 192,220 | 43,749 | 37,349 | | | 185,271 | | 108,880 | 332,551 | |
Number of unexercised warrants | | | | | | | | | | | | | | | | 46,718 | |
Warrants and rights outstanding, maturity date | | | | | | | | | | | | | | | | Dec. 30, 2020 | |
Warrant A [Member] | Letter Agreement [Member] | Medigus Ltd [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Warrant exercisable, shares | | | 43,749 | | | | | | | | | | | | | | |
Warrant B [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Warrant exercisable, shares | | | 1,000 | | 1 | | 1 | | | | | | | 1 | | | |
Warrant exerise price per share | | | $ 8.037 | | $ 8.037 | | $ 8.037 | | | | | | | $ 8.037 | | | |
Warrants and rights outstanding, term | | | 18 months | | 24 months | | 18 months | | | | | | | | 18 months | | |
Number of warrants exercised | | | | | | | | | | | | | 185,271 | | | | |
Number of unexercised warrants | 87,497 | | | | | | | | | | | | 573,256 | | 217,760 | | |
Warrants and rights outstanding, maturity date | | | | | | | | | Jun. 30, 2021 | | | | Jun. 30, 2021 | | Sep. 03, 2021 | | |
Warrant B [Member] | Letter Agreement [Member] | Medigus Ltd [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Warrant exercisable, shares | | | 87,497 | | | | | | | | | | | | | | |
Warrant [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Sale of stock, description | | | | | Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below) | | | | | | | | | | | | |
Proceeds from issuance of securities offered | | | | | $ 2,000,000 | | $ 948,000 | | | | | | | | | | |
Proceeds from issuance after deducting issuance costs | | | | | $ 1,900,000 | | $ 909,000 | | | | | | | | | | |
Common Stock [Member] | Letter Agreement [Member] | Medigus Ltd [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Number of shares conversion | | | $ 381,136 | | | | | | | | | | | | | | |
Number of shares issued | | | 87,497 | | | | | | | | | | | | | | |
Private Placement [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Stock issued during period, shares, new issues | | | | | 229,569 | | 108,880 | | | | | 379,269 | | | | | |
Shares issued, price per share | | | | | $ 8.712 | | $ 8.712 | | | | | $ 8.712 | | | | | |
Sale of stock, description | | | | | | | Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below) | | | | | Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below) | | | | | |
Proceeds from Issuance of Private Placement | | | | | | | | | | | | $ 3,300,000 | | | | | |
Board of Directors [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Common stock shares authorized | | | | | | | | | | | | | | | | | 225,000,000 |
Common stock, par value | | | | | | | | | | | | | | | | | $ 0.001 |
Board of Directors [Member] | 2020 Share Incentive Plan [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Share based compensation arrangement Options grants in period gross | | | | | | 64,099 | | | | | | | | | | | |
Consultant [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Warrant exercise price percentage | | | | | | | | | | | | | | 3% | | | |
Proceeds from exercise of warrants | | | | | | | | | | | | | | $ 2,000,000 | $ 2,000,000 | | |
Exercise of warrants required to invest return for shares of common stock | | | | | | | | | | | | | | 250,000 | | | |
Exercise of warrants required to invest return for shares of common stock | | | | | | | | | | | | | | | 250,000 | | |
Investment C [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Stock issued during period, shares, new issues | | 2,469,156 | | | | | | | | | | | | | | | |
Investors C [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Sale of stock, description | | Each such unit consists of (i) one share of common stock and (ii) one warrant to purchase one share of common stock with an exercise price of $10.35 per share | | | | | | | | | | | | | | | |
Warrant exerise price per share | | $ 10.35 | | | | | | | | | | | | | | | |
Warrants and rights outstanding, maturity date | | Mar. 31, 2026 | | | | | | | | | | | | | | | |
Proceeds from issuance of common stock | | $ 20,000,000 | | | | | | | | | | | | | | | |
Common stock percent | | 135% | | | | | | | | | | | | | | | |
Employees, Consultants, Directors and Other Service Providers [Member] | 2020 Share Incentive Plan [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Share based compensation arrangement Options grants in period gross | | | | 401,950 | | | | | | | 580,890 | | 777,778 | | | | |
Board of Directors Chairman [Member] | Share-Based Payment Arrangement, Option [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Expenses recorded regarding | | | | | | | | | | | | | | $ 213,000 | 221,000 | | |
Officer [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award | | | | | | | | | | | | | | 400,000 | | | |
Employee and Directors [Member] | | | | | | | | | | | | | | | | | |
Subsidiary, Sale of Stock [Line Items] | | | | | | | | | | | | | | | | | |
Compensation expense | | | | | | | | | | | | | | $ 1,487,000 | $ 2,030,000 | | |